Search
Close this search box.
×
Search
[custom_company_search_form]
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)

Stock Piper AI Index

Stock Piper AI Index

Subscribe
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)
Lithium
45.47
0.37%
Gold
2,666.80
0.5%
Copper
4.11
(1.01%)
Oil
69.61
0.83%
Bitcoin
97,595.91
3.44%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,863.27
0.75%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0.02%
Hang Seng
19,601.11
(0.23%)

Immutep Ltd

IMM

ASX

Immutep Limited (IMM, Prima BioMed Ltd) is a globally active biotechnology company that is a leader in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease, with currently more product candidates and programs focused on LAG-3 than any other drug development company. The Company is dedicated to leveraging its technology and expertise to discover and develop novel immunotherapies and to partner with leading organisations to bring innovative treatment options to market for patients.

Latest Posts

Line Chart with Gradient
Price
$0.285
-0.02 (-6.56%)
At Close 20/11 (AEST)
Related Companies
BLACKWALL LIMITED
$BWF
BEFOREPAY GROUP LIMITED
$B4P
WASHINGTON H SOUL PATTINSON & COMPANY LIMITED
$SOL
AUSTRALIAN BOND EXCHANGE HOLDINGS LIMITED
$ABE
NAVIGATOR GLOBAL INVESTMENTS LIMITED
$NGI

Leave a Comment on IMM


Comments for IMM

    Latest Posts

    Immutep Limited (ASX: $IMM) Reports Outstanding Results from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
    Health Care
    $imm
    Immutep Limited (ASX: $IMM) Reports Outstanding Results from INSIGHT-003 Trial in Non-Small Cell Lung CancerImmutep Limited (ASX: IMM), a clinical-stage biotechnology company, has announced positive data from its INSIGHT-003 Phase I trial, showcasing significant...
    November 14, 2024
    immutep-asx-imm-receives-rd-tax-incentive-from-french-government-imm
    Health Care $IMM

    Immutep (ASX: $IMM) receives r&d tax incentive from french government

    Receives €2,194,918 (~A$3,627,980) cash payment for R&D activities in France

    September 24, 2024
    immutep-asx-imm-announces-positive-results-from-tacti-003-trial-imm
    Health Care $IMM

    Immutep (ASX: $IMM) announces positive results from TACTI-003 trial

    Efti in combination with KEYTRUDA leads to higher response rates and durability in head and neck cancer patients

    September 16, 2024
    immuron-asx-imc-plans-phase-2-trial-for-imm-529-following-fda-review-imc
    Health Care $IMC

    Immuron (ASX: $IMC) plans phase 2 trial for imm-529 following FDA review

    Set to file IND application for IMM-529 to prevent or treat Clostridioides difficile infection

    September 5, 2024
    immutep-asx-imm-announces-first-participant-dosed-in-phase-i-study-of-imp761-a-first-in-class-agonist-lag-3-antibody-imm
    Health Care $IMM

    Immutep (ASX: $IMM) announces first participant dosed in phase i study of imp761, a first in class agonist lag-3 antibody

    Phase I trial of IMP761 aims to restore balance to immune system in autoimmune diseases

    August 14, 2024
    immutep-asx-imm-announces-successful-meeting-with-fda-on-phase-iii-design-in-non-small-cell-lung-cancer-imm
    Health Care $IMM

    Immutep (ASX: $IMM) announces successful meeting with FDA on phase III design in non-small cell lung cancer

    TACTI-004 Phase III trial to evaluate efti in combination with KEYTRUDA and standard chemotherapy

    July 22, 2024
    immutep-asx-imm-receives-regulatory-clearance-for-phase-i-study-of-first-in-class-lag-3-agonist-antibody-imm
    Health Care $IMM

    Immutep (ASX: $IMM) receives regulatory clearance for phase i study of first-in-class LAG-3 agonist antibody

    Phase I study of IMP761 to address autoimmune diseases

    July 17, 2024
    immutep-asx-imm-completes-institutional-placement-and-entitlement-offer-imm
    Health Care $IMM

    Immutep (ASX: $IMM) completes institutional placement and entitlement offer

    Raises approximately A$89.6 million from institutional investors at A$0.38 per New Share

    June 5, 2024
    immutep-asx-imm-reports-positive-initial-clinical-data-from-efti-combined-with-radiotherapy-and-checkpoint-inhibitor-imm
    Health Care $IMM

    Immutep (ASX: $IMM) reports positive initial clinical data from efti combined with radiotherapy and checkpoint inhibitor

    EFTISARC-NEO trial shows encouraging initial efficacy in soft tissue sarcoma patients

    May 2, 2024
    immutep-asx-imm-progresses-clinical-trials-and-appoints-new-director-imm
    Health Care $IMM

    Immutep (ASX: $IMM) progresses clinical trials and appoints new director

    Reports positive clinical data in breast cancer trial and advances preclinical studies for IMP761

    April 29, 2024
    immutep-asx-imm-announces-positive-preliminary-topline-results-from-tacti-003-phase-llb-trial-imm
    Health Care $IMM

    Immutep (ASX: $IMM) announces positive preliminary topline results from TACTI-003 phase llb trial

    Preliminary results show 26.9% response rate in first line metastatic head and neck squamous cell carcinoma patients

    April 24, 2024
    immutep-asx-imm-announces-first-clinical-data-from-90mg-dosing-of-efti-imm
    Health Care $IMM

    Immutep (ASX: $IMM) announces first clinical data from 90mg dosing of efti

    Safety lead-in of AIPAC-003 trial shows encouraging initial efficacy in metastatic breast cancer patients

    March 5, 2024
    immutep-asx-imm-completes-patient-enrolment-in-randomised-phase-ii-of-aipac-003-trial-imm
    Health Care $IMM

    Immutep (ASX: $IMM) completes patient enrolment in randomised phase II of AIPAC-003 trial

    Phase II trial enrols 65 metastatic breast cancer patients for eftilagimod alpha dosing study

    October 3, 2024

    IMM

    $IMM

    Immutep (ASX: $IMM) receives r&d tax incentive from french government

    Receives €2,194,918 (~A$3,627,980) cash payment for R&D activities in France

    IMM

    $IMM

    Immutep (ASX: $IMM) announces positive results from TACTI-003 trial

    Efti in combination with KEYTRUDA leads to higher response rates and durability in head and neck cancer patients

    IMC

    $IMC

    Immuron (ASX: $IMC) plans phase 2 trial for imm-529 following FDA review

    Set to file IND application for IMM-529 to prevent or treat Clostridioides difficile infection

    IMM

    $IMM

    Immutep (ASX: $IMM) announces first participant dosed in phase i study of imp761, a first in class agonist lag-3 antibody

    Phase I trial of IMP761 aims to restore balance to immune system in autoimmune diseases

    IMM

    $IMM

    Immutep (ASX: $IMM) announces successful meeting with FDA on phase III design in non-small cell lung cancer

    TACTI-004 Phase III trial to evaluate efti in combination with KEYTRUDA and standard chemotherapy

    IMM

    $IMM

    Immutep (ASX: $IMM) receives regulatory clearance for phase i study of first-in-class LAG-3 agonist antibody

    Phase I study of IMP761 to address autoimmune diseases

    IMM

    $IMM

    Immutep (ASX: $IMM) completes institutional placement and entitlement offer

    Raises approximately A$89.6 million from institutional investors at A$0.38 per New Share

    IMM

    $IMM

    Immutep (ASX: $IMM) reports positive initial clinical data from efti combined with radiotherapy and checkpoint inhibitor

    EFTISARC-NEO trial shows encouraging initial efficacy in soft tissue sarcoma patients

    IMM

    $IMM

    Immutep (ASX: $IMM) progresses clinical trials and appoints new director

    Reports positive clinical data in breast cancer trial and advances preclinical studies for IMP761

    IMM

    $IMM

    Immutep (ASX: $IMM) announces positive preliminary topline results from TACTI-003 phase llb trial

    Preliminary results show 26.9% response rate in first line metastatic head and neck squamous cell carcinoma patients

    Load More
    No More Posts
    Related Companies
    WISR LIMITED
    $WZR
    EILDON CAPITAL GROUP
    $EDC
    QUICKFEE LIMITED
    $QFE
    PRIME FINANCIAL GROUP LIMITED
    $PFG
    FINTECH CHAIN LIMITED
    $FTC

    ASX News, First
    & Fast.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    By clicking Subscribe, you agree to our Terms & Conditions
    © 2024 Stock Piper.
    All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support

    Socials

    Facebook
    Twitter
    LinkedIn
    © 2024 Stock Piper. All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support
    © 2024 Stock Piper. All rights reserved
    Social Media Auto Publish Powered By : XYZScripts.com
    Stock Piper AI Index
    Subscribe
    Join FREE Newsletter

    Stock Piper AI Index Coming Soon!

    Join our Newsletter to gain exclusive insight and be notified once we are live.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    Get all the latest market updates straight to your inbox.

    By clicking Subscribe, you agree to our Terms & Conditions